Issue Information ‐ TOC
1 October 2016
Poster Session I (Abstracts 259 – 729)
1 October 2016
Author Index
1 October 2016
Poster Session II (Abstracts 730 – 1194)
1 October 2016
Poster Session III (Abstracts 1195 – 1637)
1 October 2016
Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast
Muhammad Ali Khan, George Cholankeril, Colin W. Howden – 30 September 2016
Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis
Géraldine Dahlqvist, Farid Gaouar, Fabrice Carrat, Sofia Meurisse, Olivier Chazouillères, Raoul Poupon, Catherine Johanet, Christophe Corpechot, the French network of Immunology Laboratories – 30 September 2016 – The prevalence, clinical characteristics, and outcomes of patients with antimitochondrial antibodies (AMAs), but no clinical evidence of primary biliary cholangitis (PBC), are largely unknown. A prospective study of AMA incidence was conducted through a nation‐wide network of 63 French immunology laboratories.
Reply
Gitte Dam, Hendrik Vilstrup, Hugh Watson, Peter Jepsen – 29 September 2016
Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients
Fabrice Lainé, Marc Ruivard, Véronique Loustaud‐Ratti, Fabrice Bonnet, Paul Calès, Edouard Bardou‐Jacquet, Sylvie Sacher‐Huvelin, Xavier Causse, Christine Beusnel, Alain Renault, Eric Bellissant, Yves Deugnier, Study Group – 29 September 2016 – Dysmetabolic iron overload syndrome (DIOS) is a common cause of hyperferritinemia, accounting for a mild increase of iron stores in insulin‐resistant subjects. Iron removal could improve insulin sensitivity.
Are we moving from absence of proof to proof of absence?
Kris P. Croome, C. Burcin Taner – 29 September 2016